QTc prolongation with antipsychotics: Is routine ECG monitoring recommended?

Journal of Psychiatric Practice

Volumn 20, Issue 3, 2014, Pages 196-206

  Shah, Asim A ^a   Aftab, Awais ^b   Coverdale, John ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b KING EDWARD MEDICAL UNIVERSITY   (Pakistan)

Author keywords

Antipsychotic medications; Atypical antipsychotics; Conventional antipsychotics; ECG monitoring; QTc interval; QTc prolongation; Sudden death; Torsade de pointes

Indexed keywords

AMIODARONE; ARIPIPRAZOLE; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; DROPERIDOL; HALOPERIDOL; ILOPERIDONE; LURASIDONE; MESORIDAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PIMOZIDE; QUETIAPINE; QUINIDINE; RISPERIDONE; THIORIDAZINE; ZIPRASIDONE;

ARTICLE; CARDIOVASCULAR RISK; ELECTROCARDIOGRAPHY MONITORING; ELECTROLYTE DISTURBANCE; HUMAN; PATHOPHYSIOLOGY; PATIENT MONITORING; PRACTICE GUIDELINE; QT INTERVAL; QT PROLONGATION; SUDDEN CARDIAC DEATH; TORSADE DES POINTES; ARRHYTHMIAS, CARDIAC; CHEMICALLY INDUCED; CLASSIFICATION; DRUG EFFECTS; DRUG MONITORING; DRUG SURVEILLANCE PROGRAM; ELECTROCARDIOGRAPHY; HEART MUSCLE CONDUCTION SYSTEM; MENTAL DISORDERS; PROCEDURES; RISK ASSESSMENT; RISK FACTOR;

ANTIPSYCHOTIC AGENTS; ARRHYTHMIAS, CARDIAC; DRUG MONITORING; ELECTROCARDIOGRAPHY; HEART CONDUCTION SYSTEM; HUMANS; MENTAL DISORDERS; PHARMACOVIGILANCE; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS;

EID: 84901484152     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000450319.21859.6d     Document Type: Article

References (86)

1. De Hert M, Vancampfort D, Correll CU, et al. Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: Systematic evaluation. Br J Psychiatry 2011;199:99-105
2. Krasucki C, McFarlane F. Electrocardiograms, high-dose antipsychotic treatment and College guidelines. Psychiatr Bull 1996;20:326-30. (Pubitemid 26185108
3. Perkins DO, Lieberman JA. Medical complications and selectivity of therapeutic response to atypical antipsychotic drugs. Am J Psychiatry 1998;155:272-6. (Pubitemid 28074292
4. Fayek M, Kingsbury SJ, Zada J, et al. Psychopharma-cology: Cardiac effects of antipsychotic medications. Psychiatr Serv 2001;52:607-9. (Pubitemid 32429289
5. Francis PD. Effects of psychotropic medications on the pediatric electrocardiogram and recommendations for monitoring. Curr Opin Pediatr 2002;14:224-30. (Pubitemid 34412169
6. Taylor D. Ziprasidone in the management of schizophrenia: The QT interval issue in context. CNS Drugs 2003; 17:423-30. (Pubitemid 36560704
7. Rettenbacher MA, Eder-Ischia U, Bader A, et al. QTc variability in schizophrenia patients treated with antipsychotics and healthy controls. J Clin Psychopharmacol 2005;25:206-10. (Pubitemid 40685782
8. Abdelmawla N, Mitchell AJ. Sudden cardiac death and antipsychotics. Part 2: Monitoring and prevention. Adv Psychiatr Treat 2006;12:100-9
9. Lin YL, Wu YC, Tsai GF. Electrocardiographic monitoring for QT prolongation in patients treated with ziprasidone: A claims based database approach. Pharmacoepidemiol Drug Saf 2009;18:842-7
10. Antzelevitch C. Ionic, molecular, and cellular bases of QTinterval prolongation and torsade de pointes. Europace 2007;9(suppl 4):4-15
11. Pentti MR, Surawicz B, Gettes L. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: Part IV. J Am Coll Cardiol 2009; 53:982-91
12. Bernstein JE. Recognizing when long QT intervals mean trouble. Nursing 1997;27:32aa-32ff
13. Al-Khatib SM, LaPointe NMA, Kramer JM, et al. What clinicians should know about the QT interval. JAMA 2003; 289:2120-7. (Pubitemid 37430214
14. Aberg K, Adkins DE, Liu Y, et al. Genome-wide association study of antipsychotic-induced QTc interval prolongation. Pharmacogenomics J 2010;12:165-72
15. Dogan A, Tunc E, Varol E, et al. Comparison of the four formulas of adjusting QT interval for the heart rate in the middle-Aged healthy Turkish men. Ann Noninvasive Electrocardiol 2005;10:134-41. (Pubitemid 40646653
16. Batchvarov VN, Ghuran A, Smetana P, et al. QT-RR relationship in healthy subjects exhibits substantial intersubject variability and high intrasubject stability. Am J Physiol Heart Circ Physiol 2002;282:H2356-63
17. de Bruyne MC, Hoes AW, Kors JA, at al. Prolonged QT interval predicts cardiac and all-cause mortality in the elderly: The Rotterdam Study. Eur Heart J 1999;20:278-84
18. Eli Lilly Co. QTc prolongation and increased cardiac risks. Psychiatric News Jan 5, 2001:22-3
19. Moss AJ. Drug-induced QT prolongation: An update. Ann Noninvasive Electrocardiol 2006;11:1-2
20. Committee for Proprietary Medicinal Products. Points to consider: The assessment for the potential for QT prolongation by non-cardiovascular medicinal products. Report #CPMP/986/96. London: European Agency for the Evalu-Ation of Medicinal Products; 1997
21. Schouten EG, Dekker JM, Meppelink P, et al. QT interval prolongation predicts cardiovascular mortality in an apparently healthy population. Circulation 1991;84: 1516-23
22. Bednar MM, Harrigan EP, Anziano RJ, et al. The QT interval. Prog Cardiovas Dis 2001;43:1-45. (Pubitemid 32223496
23. Nguyen PT, Scheinman MM, Seger J. Polymorphous ventricular tachycardia: Clinical characterization, therapy, and the QT interval. Circulation 1986;74:340-9. (Pubitemid 16072129
24. Thomas M, Maconochie JG, Fletcher E. The dilemma of the prolonged QT interval in early drug studies. Br J Clin Pharmacol 1996;41:77-81. (Pubitemid 26059121
25. Schwartz PJ, Locati E. The idiopathic long QT syndrome: Pathogenetic mechanisms and therapy. Eur Heart J 1985;6(suppl D):103-14. (Pubitemid 16172260
26. Rubart M, Pressler ML, Pride HP, et al. Electro-physiological mechanisms in a canine model of erythromycin-Associated long QT syndrome. Circulation 1993;88: 1832-44. (Pubitemid 23296931
27. Patterson SD. Investigating drug-induced QT and QTc prolongation in the clinic: A review of statistical design and analysis considerations: Report from the Pharma-ceutical Research and Manufacturers of America QT Statistics Expert Team. Drug Information Journal 2005; 39:243-65
28. U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for industry: E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-Antiarrhythmic drugs. October, 2005 (available at www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM073153.pdf, accessed March 20, 2014
29. ICH Harmonised Tripartite Guideline. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for nonantiarrhythmic drugs E14. Recommended for adoption at Step 4. 2005 (available at http://www.ich .org/fileadmin /Public-Web-Site/ICH-Products/Guidelines/Efficacy/E14/E14-Guideline.pdf, accessed April 27, 2014
30. Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and pro-Arrhythmia by non-Antiarrhythmic drugs: Clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res 2000;47:219-33
31. Camm AJ, Malik M; Yap YG. Acquired long QT syndrome. London: Blackwell Futura; 2004
32. Moss AJ. Measurement of the QT interval and the risk associated with QTc interval prolongation: A review. Am J Cardiol 1993;72:23B-25B.
33. Glassman AH, Bigger JT. Antipsychotic drugs: Prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001;158:1774-82. (Pubitemid 33054769
34. Zeltser D, Justo D, Halkin A, et al. Torsade de pointes due to noncardiac drugs: Most patients have easily identifiable risk factors. Medicine 2003;82:282-90. (Pubitemid 36859224
35. Darpo B. Spectrum of drugs prolonging QT interval and the incidence of torsade de pointes. Eur Heart J Suppl 2001;3(suppl K):K70-K80
36. Jolly K, Gammage MD, Cheng KK. Sudden death in patients receiving drugs tending to prolong the QT interval. Br J Clin Pharmacol 2009;68:743-51
37. Haddad PM, Anderson IM. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 2002;62:1649-71. (Pubitemid 34848372
38. Modell SM, Bradley DJ, Lehmann MH. Genetic testing for long QT syndrome and the category of cardiac ion channelopathies. PLoS Currents 2012 May 3;e4f9995f69e6c7
39. Sala M, Vicentini A, Brambilla P, et al. QT interval prolongation related to psychoactive drug treatment: A comparison of monotherapy versus polytherapy. Ann Gen Psychi atry 2005;4:1
40. Brown D, Giles W. Impaired fasting glucose, diabetes mellitus, and cardiovascular disease risk factors are associated with prolonged QTc duration. Results from the Third National Health and Nutrition Examination Survey. J Cardiovasc Risk 2001;8:227-33. (Pubitemid 32803677
41. Slama TG. Minimizing the risk of QT interval prolongation. J Fam Pract 2005;S15-7
42. Fukui S, Hiroshi K. Multivariate analysis of risk factors for T prolongation following subarachnoid hemorrhage. Critical Care 2003;7:7-12
43. Sesti F, Abbott GW, Wei J, et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci U S A 2000;97:10613-8
44. Camm AJ, Janse MJ, Roden DM, et al. Congenital and acquired long QT syndrome. Eur Heart J 2000;21:1232-7. (Pubitemid 30487770
45. Robert PW. Cardiovascular effects of antipsychotics used in bipolar illness. J Clin Psychiatry 2002;63:20-3
46. Vieweg WV. New generation antipsychotic drugs and QTc interval prolongation. Prim Care Companion J Clin Psychiatry 2003;5:205-15
47. Lawrence PH. Increased risk of sudden cardiac death with typical and atypical antipsychotics. Psychopharmacology Update 2009;20:4-6
48. Sacks MH, Bonforte RJ, Laser RP, et al. Cardiovascular complications of imipramine intoxication. JAMA 1968; 205:588-90
49. Kelly HG, Fay JE, Lavery SG. Thioridazine hydrochloride (Mellaril): Its effects on the electrocardiogram and a report of two fatalities with electrocardiographic abnormalities. Can Med Assoc J 1963;89:546-54
50. Mehta D, Mehta S, Petit J, et al. Cardiac arrhythmia and haloperidol. Am J Psychiatry 1979;136:1468-9. (Pubitemid 10194792
51. Roden DM, Lazzara R, Rosen M, et al. Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS. Circulation 1996;94:1996-2012
52. Hennessy S, Bilker WB, Knauss JS, et al. Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: Cohort study using administrative data. BMJ 2002;325:1070-4
53. Ray WA, Meredith S, Thapa PB, et al. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry 2001;58:1161-7. (Pubitemid 33121508
54. Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009;360:225-35
55. Novotny T, Florianova A, Ceskova E, et al. Monitoring of QT interval in patients treated with psychotropic drugs. Int J Cardiol 2007;117:329-32. (Pubitemid 46507624
56. FDA Psychopharmacological Drugs Advisory Committee. Briefing document for Zeldox capsules (ziprasidone HCl). New York: Pfizer, Inc: July 19, 2000: 4, 78, 80 (available at www.fda.gov/ohrms/dockets/ac/00/backgrd/3619b1a.pdf, accessed March 21, 2014
57. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psy-chiatry 2004;161:1334-49. (Pubitemid 38989085
58. Hoehns JD, Stanford RH, Geraets DR, et al. Torsade de pointes associated with chlorpromazine: Case report and review of associated ventricular arrhythmias. Pharmaco-Therapy 2001;21:871-83. (Pubitemid 32606801
59. Reilly JG, Ayis SA, Ferrier IN, et al. QTc abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000;355:1048-52. (Pubitemid 30162807
60. Jackson T, Ditmanson L, Phibbs B. Torsade de pointes and low-dose oral haloperidol. Arch Intern Med 1997;157: 2013-5. (Pubitemid 27398366
61. Hassaballa HA, Balk RA. Torsade de pointes associated with the administration of intravenous haloperidol: A review of the literature and practical guidelines for use. Exp Opin Drug Saf 2003;2:543-7
62. Haloperidol injection prescribing information. New York: Pfizer; revised April 2011 (available at www.pfizer.com/files/products/uspi-haloperidol.pdf, accessed: March 21, 2014
63. Meyer-Massetti C, Cheng CM, Sharpe BA, et al. The FDA extended warning for intravenous haloperidol and torsade de pointes: How should institutions respond?. J Hosp Med 2010;5:E8-16
64. Sertindole NDA 20-644. Rockville, MD: U.S. Food and Drug Administration, Psychopharmacological Drugs Advisory Committee; 1996
65. FDA Psychopharmacological Drugs Advisory Committee. Briefing document for Zeldox capsules (ziprasidone HCl). New York: Pfizer, Inc: July 19, 2000: 107 (available atwww.fda.gv/ohrms/dockets/ac/00/backgrd/3619b1a.pdf, accessed March 21, 2014
66. FDA Psychopharmacological Drugs Advisory Committee. Briefing document for Zeldox capsules (ziprasidone HCl). New York: Pfizer, Inc: July 19, 2000: 68 (available at www.fda.gv/ohrms/dockets/ac/00/backgrd/3619b1a.pdf, accessed March 21, 2014
67. Heinrich TW, Biblo LA, Schneider J. Torsade de pointes associated with ziprasidone. Psychosomatics 2006;47: 264-8
68. Ellingrod VL. Which psychotropics carry the greatest risk of QTc prolongation?. Current Psychiatry 2012;11:36-9
69. Kang UG, Kwon JS, Ahn YM, et al. Electrocardiographic abnormalities in patients treated with clozapine. J Clin Psychiatry 2000;61:441-6. (Pubitemid 30452212
70. Wenzel-Seifert K, Wittmann M, Haen E. QTc prolongation by psychotropic drugs and the risk of torsade de pointes. Deutsches Ärzteblatt International 2001;108:687
71. Goodnick PJ, Jerry JM. Aripiprazole: Profile on efficacy and safety. Expert Opin Pharmacother 2002;3:1773-81. (Pubitemid 36054598
72. Goodnick PJ, Jerry J, Parra F. Psychotropic drugs and the ECG: Focus on the QTc interval. Expert Opin Pharmaco-Ther 2002;3:479-98. (Pubitemid 34520859
73. ABILIFY (aripiprazole) prescribing Information. Tokyo: Otsuka; revised February 2012 (available at www.accessdata. fda.gov/drugsatfda-docs/label/2012/ 021436s034,0217 13s025,021729s018,021866s020lbl.pdf, accessed March 21, 2012
74. Nelson S, Leung JG. Torsade de pointes after administration of low-dose aripiprazole. Ann Pharmacother 2013;47: E11
75. Citrome L. Lurasidone for schizophrenia: A review of the efficacy and safety profile for this newly approved secondgeneration antipsychotic. Int J Clin Pract 2011;65: 189-210
76. U.S. Food and Drug Administration. Drug approval package: Latuda (lurasidone hydrochloride) tablets (available at www.accessdata.fda.gov/ drugsatfda-docs/nda/2010/200603Orig1s000TOC.cfm, accessed March 21, 2014
77. Latuda (lurasidone HCl) tablets prescribing information . Marlborough, MA: Sunovion; July 2013 (available at www.latuda.com/ LatudaPrescribingInformation.pdf, accessed March 21, 2014
78. Fanapt (iloperidone) prescribing information. East Hanover, NJ: Novartis; January 2013 (available at www.accessdata.fda.gov/drugsatfda-docs/label/2013/ 0221 92s007lbl.pdf, accessed March 21, 2013
79. Cutler AJ, Kalali AH, Weiden PJ, et al. Four week, doubleblind, placebo-And ziprasidone-controlled trial of iloperidone in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol 2008;28(2 Suppl 1):S20-8
80. Caccia S, Pasina L, Nobili A. New atypical antipsychotics for schizophrenia: Iloperidone. Drug Des Devel Ther 2010; 4:33-48
81. Kramer M, Litman R, Hough D, et al. Paliperidone palmitate, a potential long-Acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuro-psychopharmacol 2010;13:635-7
82. Gopal S, Hough DW, Xu H, et al. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: A randomized, double-blind, placebo-controlled, dose-response study. Int Clin Psycho-pharmacol 2010;25:247-56
83. Gopal S, Vijapurkar U, Lim P, et al. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. Journal of Psycho-phar macology 2001;25:685-97
84. Chapel S, Hutmacher MM, Haig G, et al. Exposureresponse analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation. J Clin Pharmacol 2009;49:1297-1308
85. Drew BJ, Califf RM, Funk M, et al. AHA scientific statement: Practice standards for electrocardiographic monitoring in hospital settings: An American Heart Association scientific statement from the Councils on Cardiovascular Nursing, Clinical Cardiology, and Cardiovascular Disease in the Young: Endorsed by the International Society of Computerized Electrocardiology and the American Association of Critical-Care Nurses. J Cardiovasc Nurs 2005;20:76-106
86. Rembold CM. Number needed to screen: Development of a statistic for disease screening. BMJ 1998;317:307-12. (Pubitemid 28353824.